Chikungunya 01 Bell 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

7

Download PDF ↗ Live URL (may be dead)

Document text

CHIKUNGUNYA VACCINES
Beth Bell, MD, MPH
Chair, ACIP Chikungunya Vaccines Work GroupACIP Meeting
February 23, 2023
Background
Valneva completed submission of Biologics License Application (BLA) for 
their chikungunya vaccine to FDA in December 2022
No chikungunya vaccine ever licensed in United States or globally
No existing ACIP chikungunya vaccine recommendations
Chikungunya Vaccines Work Group formed in May 2022 to develop policy options for ACIP’s consideration for use of chikungunya vaccine among U.S. 
persons at risk of chikungunya, including 
–Travelers
–Residents of U.S. territories and states with, or at risk of, transmission
–Laboratory workers
Terms of Reference for Chikungunya Vaccines Work Group 
To review information on chikungunya disease, including outcomes
To review data on chikungunya epidemiology and burden among U.S. residents, 
including travelers and persons living in areas at risk for local transmission
To review data on safety, immunogenicity, and effectiveness of chikungunya 
vaccines 
To provide evidence -based recommendation options for ACIP
To identify areas in need of further research for informing potential future vaccine recommendations
To publish a chikungunya vaccine MMWR Recommendations and Reports document
ACIP Ex Officio Invited Consultants
Beth Bell, Univ Washington (Chair) Robin Levis, FDA Alan Barrett, Univ Texas Galveston
Wilbur Chen, Univ Maryland Sixun Yang, FDA Carina Blackmore, Florida Dept Health
Lesley Dupuy, NIH Alan Lam, DoD
CDC Leads Margaret Ryan, DoD
Susan Hills, DVBD (Lead) ACIP Liaisons Steven Schofield, CATMAT
Nicole Lindsey, DVBD (Deputy Lead) Paschal Apanga, AIM David Shlim, Jackson Hole Travel & Trop Med
Elizabeth Barnett, ISTM Nestor Sosa, Uni New Mexico Hospital
James Campbell, AAP Sanet Torres, San Jorge Children & Women's Hospital
Mary Pat Friedlander, AAFP Kirsten Vannice, Bill & Melinda Gates Foundation
Mary Wilson, Univ California San FranciscoChikungunya Vaccines Work Group members
DVBD DGMQ ISD
Erin Staples Sarah Guagliardo Elisabeth Velazque z
Ann Powers
Laura Adams DHQP GRADE/ETR consultants
Joshua Wong Michael McNeil Doug Campos -Outcalt
Rebecca Morgan
NCEZID GID
Rita Helfand Rebecca Casey ACIP Secretariat
Jessica MacNeil, NCIRD
Leslie Lee, NCIRDChikungunya Vaccines Work Group CDC participants
Recap of previous Work Group presentations to ACIP 
October 2022
–Overview of chikungunya virus disease and vaccines
–Immunogenicity and safety of Valneva’s chikungunya vaccine
Overview of today’s session
Global epidemiology of chikungunya
–Dr. Susan Hills (CDC/NCEZID)
Chikungunya in U.S. travelers
–Ms. Nicole Lindsey (CDC/NCEZID)
Persistent arthralgia following chikungunya
–Ms. Nicole Lindsey (CDC/NCEZID)
Work Group considerations
–Ms. Nicole Lindsey (CDC/NCEZID)